Optimization Strategy to Minimize Wastage of Palivizumab during the 2008 RSV Season in Sao Paulo, Brazil

Weckx, Lily Yin; Monteiro, Ana Isabel Melo Pereira; Souza, Alessandra R.; Moraes-Pinto, Maria Isabel de

doi:10.1093/tropej/fmp003

Cited by 4 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, palivizumab is recommended as a preventive measure in high-risk settings. Unfortunately, this agent is too costly for use in developing countries [19]. Therefore, the development of an efficient vaccine should remain a high priority in managing RSV infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in southern Brazil

de‐Paris¹,

Beck²,

Nunes³

et al. 2014

Virol J

View full text Add to dashboard Cite

BackgroundRespiratory syncytial virus (RSV) is the main cause of lower respiratory tract illness in children worldwide. Molecular analyses show two distinct RSV groups (A and B) that comprise different genotypes. This variability contributes to the capacity of RSV to cause yearly outbreaks. These RSV genotypes circulate within the community and within hospital wards. RSV is currently the leading cause of nosocomial respiratory tract infections in pediatric populations. The aim of this study was to evaluate the G protein gene diversity of RSV amplicons.MethodsNasopharyngeal aspirate samples were collected from children with nosocomial or community-acquired infections. Sixty-three RSV samples (21 nosocomial and 42 community-acquired) were evaluated and classified as RSV-A or RSV-B by real-time PCR. Sequencing of the second variable region of the G protein gene was performed to establish RSV phylogenetics.ResultsWe observed co-circulation of RSV-A and RSV-B, with RSV-A as the predominant group. All nosocomial and community-acquired RSV-A samples were from the same phylogenetic group, comprising the NA1 genotype, and all RSV-B samples (nosocomial and community-acquired) were of the BA4 genotype. Therefore, in both RSV groups (nosocomial and community-acquired), the isolates belonged to only one genotype in circulation.ConclusionsThis is the first study to describe circulation of the NA1 RSV genotype in Brazil. Furthermore, this study showed that the BA4 genotype remains in circulation. Deciphering worldwide RSV genetic variability will aid vaccine design and development.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Palivizumab is a humanized monoclonal antibody that is currently recommended as prophylaxis for certain patient groups at risk of severe RSV infection [18]. However, it is too expensive for wide-range use in developing countries such as Brazil [19]. …”

Section: Introductionmentioning

confidence: 99%

Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in southern Brazil

de‐Paris¹,

Beck²,

Nunes³

et al. 2014

Virol J

View full text Add to dashboard Cite

show abstract

“…The optimization strategy of the administration of palivizumab with grouped scheduling led to an economy of 28.2%, with the use of 749.1mL of palivizumab, in comparison to 1,044mL that would have been used in case of individual scheduling ( 25 ) .…”

Section: Discussionmentioning

confidence: 99%

“…A estratégia de otimização da administração do palivizumabe com agendamento agrupado levou a uma economia de 28,2%, com uso de 749,1mL do palivizumabe, em comparação a 1.044mL que teriam sido utilizados em caso de agendamento individual ( 25 ) .…”

Section: Discussionunclassified

Respiratory infections in children up to two years of age on prophylaxis with palivizumab

Monteiro

Bellei

Sousa

et al. 2014

Rev. paul. pediatr.

View full text Add to dashboard Cite

OBJECTIVE:To identify the viruses involved in acute respiratory tract infections and to analyze the rates of hospitalization and death in children on palivizumab prophylaxis.METHODS:Prospective cohort of 198 infants up to one year old who were born before 29 weeks of gestational age and infants under two years old with hemodynamically unstable cardiopathy or chronic pulmonary disease who received prophylactic palivizumab against severe respiratory syncytial virus infections in 2008. During the study period, in each episode of acute respiratory tract infection, nasopharyngeal aspirate was collected to identify respiratory syncytial virus, adenovirus, parainfluenza 1, 2 and 3, influenza A and B by direct immunofluorescence, rhinovirus and metapneumovirus by polymerase chain reaction preceded by reverse transcription. Data regarding hospitalization and deaths were monitored.RESULTS:Among the 198 studied infants, 117 (59.1%) presented acute respiratory tract infections, with a total of 175 episodes. Of the 76 nasopharyngeal aspirates collected during respiratory tract infections, 37 were positive, as follow: rhinovirus (75.7%), respiratory syncytial virus (18.9%), parainfluenza (8.1%), adenovirus 2 (2.7%), metapneumovirus (2.7%) and three samples presented multiple agents. Of the 198 children, 48 (24.4%) were hospitalized: 30 (15.2%) for non-infectious etiology and 18 (9.1%) for respiratory causes. Among these 18 children, one case of respiratory syncytial virus was identified. Two deaths were reported, but respiratory syncytial virus was not identified.CONCLUSIONS:During the prophylaxis period, low frequency of respiratory syncytial virus infections and low rates of hospitalization were observed, suggesting the benefit of palivizumab prophylaxis.

show abstract

“…Despite its proven efficacy in reducing hospitalizations attributable to RSV, palivizumab is still exceedingly expensive for developing countries such as Brazil. Therefore, reducing costs through the optimization of drug administration may allow more children to benefi t from RSV prophylaxis 10 . Concerning nosocomial infections, RSV is the foremost cause of hospital-acquired respiratory infections among children 8 .…”

mentioning

confidence: 99%

Viral epidemiology of respiratory infections among children at a tertiary hospital in Southern Brazil

de‐Paris

Beck

Pires

et al. 2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Optimization Strategy to Minimize Wastage of Palivizumab during the 2008 RSV Season in Sao Paulo, Brazil

Cited by 4 publications

References 5 publications

Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in southern Brazil

Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in southern Brazil

Respiratory infections in children up to two years of age on prophylaxis with palivizumab

Viral epidemiology of respiratory infections among children at a tertiary hospital in Southern Brazil

Contact Info

Product

Resources

About